Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-...
Barclays analyst Gena Wang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and lowers the price target from...
Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target fro...
Guggenheim analyst Debjit Chattopadhyay maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target ...
Mizuho analyst Uy Ear upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Neutral to Outperform and raises the price target fro...
